Aerobic exercise combined with antioxidative treatment does not counteract moderate- or mid-stage alzheimer-like pathophysiology of APP/PS1 mice

CNS Neuroscience and Therapeutics

Volumn 19, Issue 10, 2013, Pages 795-803

  Xu, Zhi Qiang ^a   Zhang, Lu Qing ^a   Wang, Qin ^b   Marshall, Charles ^c   Xiao, Na ^a   Gao, Jun Ying ^a   Wu, Ting ^b   Ding, Jiong ^a   Hu, Gang ^a   Xiao, Ming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

amyloid; Aerobic exercise; Alzheimer's disease; Antioxidative treatment; APP PS1 mice; Cognitive function; Pathology

Indexed keywords

3 NITROTYROSINE; ACETYLCYSTEINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; GLIAL FIBRILLARY ACIDIC PROTEIN; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; PEROXIREDOXIN 1; PROTEIN; SYNAPTOPHYSIN; THIOFLAVINE; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DISEASE SEVERITY; FOREBRAIN; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAZE TEST; MEMORY; MORRIS WATER MAZE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SPATIAL LEARNING; STAINING; STRESS; WESTERN BLOTTING; WILD TYPE;

AEROBIC EXERCISE; ALZHEIMER'S DISEASE; ANTIOXIDATIVE TREATMENT; APP/PS1 MICE; COGNITIVE FUNCTION; PATHOLOGY; Β-AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; COMBINED MODALITY THERAPY; INFLAMMATION; MICE; MICE, TRANSGENIC; PHYSICAL CONDITIONING, ANIMAL; PRESENILIN-1; TREATMENT OUTCOME;

EID: 84884816645     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12139     Document Type: Article

References (59)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
2. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012;97:38-51.
3. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010;56:484-546.
4. Mullane K, Williams M. Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 2013;85:289-305.
5. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005;99:1193-1204.
6. van Praag H. Exercise and the brain: Something to chew on. Trends Neurosci 2009;32:283-290.
7. Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010;68:311-318.
8. Albeck DS, Sano K, Prewitt GE, Dalton L. Mild forced treadmill exercise enhances spatial learning in the aged rat. Behav Brain Res 2006;168:345-348.
9. Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005;25:4217-4221.
10. Sofi F, Valecchi D, Bacci D, et al. Physical activity and risk of cognitive decline: A meta-analysis of prospective studies. J Intern Med 2011;269:107-117.
11. Korczyn AD. AD: Are we intervening too late? J Neural Transm 2011;118:1359.
12. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-641.
13. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008;60:748-766.
14. Shen C, Chen Y, Liu H, et al. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem 2008;283:17721-17730.
15. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. J Neurochem 2006;96:1-13.
16. Tamagno E, Guglielmotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 2008;104:683-695.
17. Corbi G, Conti V, Russomanno G, et al. Is physical activity able to modify oxidative damage in cardiovascular aging? Oxid Med Cell Longev 2012;2012:728547.
18. Powers SK, Nelson WB, Hudson MB. Exercise-induced oxidative stress in humans: Cause and consequences. Free Radic Biol Med 2011;51:942-950.
19. Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002;61:191-202.
20. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012;1822:625-630.
21. Fu AL, Dong ZH, Sun MJ. Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res 2006;1109:201-206.
22. Hsiao YH, Kuo JR, Chen SH, Gean PW. Amelioration of social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit by N-acetylcysteine in a transgenic mouse model. Neurobiol Dis 2012;45:1111-1120.
23. Liu J, Cao L, Chen J, et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009;459:387-392.
24. Li L, Ding J, Marshall C, Gao J, Hu G, Xiao M. Pretraining affects Morris water maze performance with different patterns between control and ovariectomized plus D-galactose-injected mice. Behav Brain Res 2011;217:244-247.
25. Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000;48:1223-1232.
26. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates, 2nd edn. Amsterdam: Elsevier, 2008.
27. Fishman CE, Cummins DJ, Bales KR, et al. Statistical aspects of quantitative image analysis of beta-amyloid in the APP(V717F) transgenic mouse model of Alzheimer's disease. J Neurosci Methods 2001;108:145-152.
28. Hua X, Lei M, Zhang Y, et al. Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. Life Sci 2007;80:1897-1905.
29. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004;55:801-814.
30. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci 2011;14:750-756.
31. Butterfield DA, Reed T, Sultana R. Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic Res 2011;45:59-72.
32. Bell KF, Hardingham GE. CNS peroxiredoxins and their regulation in health and disease. Antioxid Redox Signal 2011;14:1467-1477.
33. Cimini A, Gentile R, Angelucci F, et al. Neuroprotective effects of PrxI over-expression in an in vitro human Alzheimer's disease model. J Cell Biochem 2013;114:708-715.
34. Clare R, King VG, Wirenfeldt M, Vinters HV. Synapse loss in dementias. J Neurosci Res 2010;88:2083-2090.
35. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 2004;24:6457-6465.
36. Malthankar-Phatak G, Poplawski S, Toraskar N, Siman R. Combination therapy prevents amyloid-dependent and -independent structural changes. Neurobiol Aging 2012;33:1273-1283.
37. Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 2008;13:359-369.
38. Ke HC, Huang HJ, Liang KC, Hsieh-Li HM. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non-shock treadmill exercise. Brain Res 2011;1403:1-11.
39. Maesako M, Uemura K, Kubota M, et al. Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 2012;287:23024-23033.
40. Liu HL, Zhao G, Cai K, Zhao HH, Shi LD. Treadmill exercise prevents decline in spatial learning and memory in APP/PS1 transgenic mice through improvement of hippocampal long-term potentiation. Behav Brain Res 2011;218:308-314.
41. García-Mesa Y, López-Ramos JC, Giménez-Llort L, et al. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J Alzheimers Dis 2011;24:421-454.
42. Herring A, Donath A, Yarmolenko M, et al. Exercise during pregnancy mitigates Alzheimer-like pathology in mouse offspring. FASEB J 2012;26:117-128.
43. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial. JAMA 2008;300:1027-1037.
44. Baker LD, Bayer-Carter JL, Skinner J, et al. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment. J Alzheimers Dis 2012;28:137-146.
45. Winchester J, Dick MB, Gillen D, et al. Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. Arch Gerontol Geriatr 2013;56:96-103.
46. Richter H, Ambrée O, Lewejohann L, et al. Wheel-running in a transgenic mouse model of Alzheimer's disease: Protection or symptom? Behav Brain Res 2008;190:74-84.
47. van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 1999;2:266-270.
48. Querido JS, Sheel AW. Regulation of cerebral blood flow during exercise. Sports Med 2007;37:765-782.
49. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends Neurosci 2007;30:464-472.
50. Willie CK, Cowan EC, Ainslie PN, et al. Neurovascular coupling and distribution of cerebral blood flow during exercise. J Neurosci Methods 2011;198:270-273.
51. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: Disease cause or consequence? J Cereb Blood Flow Metab 2012;32:1207-1221.
52. Jeynes B, Provias J. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res 2011;89:22-28.
53. Nicolakakis N, Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab 2011;31:1354-1370.
54. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-767.
55. Lovell MA, Xiong S, Lyubartseva G, Markesbery WR. Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med 2009;46:1527-1533.
56. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2004;18:323-325.
57. Quinn J, Kulhanek D, Nowlin J, et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. Brain Res 2005;1037:209-213.
58. Dragicevic N, Copes N, O'Neal-Moffitt G, et al. Melatonin treatment restores mitochondrial function in Alzheimer's mice: A mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 2011;51:75-86.
59. Yang X, Dai G, Li G, Yang ES. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2010;41:110-113.